Report Library
All Reports
Multiple Sclerosis KOL Insight Interview
October 28, 2014
BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all
reports
and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker
or call
BioMedTracker
Client Services at (858) 200-2357.
KOL Highlights
To purchase the full Multiple Sclerosis KOL Insight Interview, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
KOL Highlights
- The Receptos RPC1063 data itself is not a surprise; it’s in-line with what we see with Gilenya.(RCPT)
- Unimpressed with daclizumab Phase III DECIDE data. (BIIB)
- Long-term data for Tecfidera shows that people are starting to work out some of the side effect issues. (BIIB)
- Tysabri is a great drug for patients with agressive disease, but the downside of PML risk. If JCV virus index is 0.9 or below - there is a low threshold to start treatment. (BIIB)
- anti-LINGO will likely have mild to modest disease modifying effects in humans. (BIIB)
To purchase the full Multiple Sclerosis KOL Insight Interview, click the link at the top of the page.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: | Neurology |
| Indications Covered: |
Guillain-Barré Syndrome
Ischemic Stroke Optic Neuritis (Ophthalmology) Post-Traumatic Stress Disorder (PTSD) Premenstrual Dysphoric Disorder (PMDD) Sleep Apnea Smoking Cessation Substance Use Disorder |
Additional Resources: